RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

This study represents first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Rosie Marder, a New York-based writer for Travel + Leisure, specializes in finding top travel product deals. Constantly scouring the web for the best prices on fashion, beauty, and travel products ...

Here, we reveal the models that impressed our expert lab tests. If you just want to see our favourite sets then check out the best TVs we've tested. Before we get to the best models, it's important to ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 ...

Glucotrack (Nasdaq:GCTK) today said it hit a significant milestone in the development of its continuous blood glucose monitor (CBGM). Our sister site, Drug Delivery Business News, reports today ...

today announced that updated preclinical data for its continuous blood glucose monitor (“CBGM”) will be presented at the 24th An Biotech veteran joins Glucotrack’s Board to support bringing ...